**Claims**

1. Use of a paliperidone palmitate extended-release injectable suspension in the manufacture of a medicament for the treatment of schizophrenia in a patient, wherein the use comprises the paliperidone palmitate extended-release injectable suspension to be administered from a syringe, wherein the syringe has undergone pre-shipping storage and has been shipped, and wherein the syringe has been maintained in an orientation during the shipping that varies from the orientation of the syringe during pre-shipping storage.

2. The use according to claim 1, wherein the pre-shipping storage orientation was tip down, and the shipping orientation is tip up or substantially horizontal.

3. The use according to claim 1 or claim 2, wherein the pre-shipping storage orientation was tip down, and the shipping orientation is substantially horizontal.

4. The use according to any one of claims 1-3, wherein the suspension contains about 273, 410, 546, or 819 mg of paliperidone palmitate.

5. The use according to any one of claims 1-4, wherein the suspension contains about 1092 or 1560 mg of paliperidone palmitate.

6. A method for improving resuspendability of a paliperidone palmitate extended-release injectable suspension within a syringe comprising maintaining the syringe in a desired orientation during shipping of the syringe that varies from the orientation of the syringe during pre-shipping storage.

7. The method according to claim 6, wherein maintaining the syringe in the desired shipping orientation comprises loading the syringe onto a shipping vehicle in the desired orientation, monitoring the syringe during shipping to confirm maintenance of the desired orientation, or both.

8. The method according to claim 6 or claim 7, further comprising housing the syringe within a container comprising an outer surface that bears instructions for maintaining the container during shipping in an orientation that corresponds to the desired orientation of the syringe.

9. The method according to any one of claims 6-8, further comprising housing the syringe within a container comprising an outer surface that bears markings that indicate an orientation of the container that corresponds to maintaining the desired orientation.

10. The method according to any one of claims 6-9, further comprising, subsequent to shipping of the syringe, maintaining the syringe at a storage location in a substantially horizontal orientation.

11. The method according to any one of claims 6-10, wherein the syringe is shipped by airplane, truck, boat, or railroad.

12. The method according to any one of claims 6-11, wherein, following the shipping, the syringe contains no more than about 1.5 mm of residue representing non-resuspended paliperidone palmitate after administration.

13. The method according to any one of claims 6-12, wherein, following the shipping, the syringe contains no more than about 1 mm of residue representing non-resuspended paliperidone palmitate after administration.

14. The method according to any one of claims 6-13, wherein the syringe has a capacity of 1 mL, 2.25 mL, 2.8 mL, or 3mL and includes a 22 gauge needle that is 1 or 1.5 inches long.

15. The method according to any one of claims 6-13, wherein the syringe has a capacity of 5 mL, and includes a 20 gauge needle that is 1.5 inches long.

16. The method according to any one of claims 6-15, wherein the suspension contains about 273, 410, 546, or 819 mg of paliperidone palmitate.

17. The method according to any one of claims 6-15, wherein the suspension contains about 1092 or 1560 mg of paliperidone palmitate.

18. The method according to any one of claims 6-17, further comprising the suspension to be administered from the syringe to a patient.

19. The method according to any one of claims 6-18, wherein the desired shipping orientation is substantially horizontal, tip up, or tip down.

20. The method according to any one of claims 6-19, wherein the desired shipping orientation varies from the orientation of the syringe during pre-shipping storage by about 45 degrees to about 135 degrees.

21. The method according to any one of claims 6-20, wherein the pre-shipping storage orientation is tip down, and the shipping orientation is tip up or substantially horizontal.

22. The method according to any one of claims 6-21, wherein the pre-shipping storage orientation is tip down, and the shipping orientation is substantially horizontal.

23. A method for reducing a force required for injection of a paliperidone palmitate extended-release injectable suspension from a syringe comprising maintaining the syringe in a desired orientation during shipping of the syringe that varies from the orientation of the syringe during pre-shipping storage.

24. The method according to claim 23, wherein the force required for injection from the syringe is about 20% to about 50% less than a force required for injection of a paliperidone palmitate extended-release injectable suspension from a syringe that was maintained in an orientation during shipping of the syringe that is substantially the same as the orientation of the syringe during pre-shipping storage.

25. The method according to claim 23 or claim 24, wherein the force required for injection from the syringe is about 10-25 Newtons less than a force required for injection of a paliperidone palmitate extended-release injectable suspension from a syringe that was not maintained in the desired orientation during shipping of the syringe.

26. The method according to any one of claims 23-25, wherein the force required for injection from the syringe is about 10-25 Newtons.

27. The method according to any one of claims 23-26, further comprising assessing the force required to complete an injection of the paliperidone palmitate extended-release injectable suspension from the syringe.

28. A method for reducing the likelihood of incomplete injection of a paliperidone palmitate extended-release injectable suspension from a syringe comprising maintaining the syringe in a desired orientation during shipping of the syringe that varies from the orientation of the syringe during pre-shipping storage.

29. The method according to claim 28, further comprising assessing whether an injection of the paliperidone palmitate extended-release injectable suspension from the syringe is complete.

30. A population of syringes that respectively contain paliperidone palmitate extended release injectable suspension, wherein each of the syringes have been stored prior to shipping and shipped to a destination, and the syringes were each maintained in a desired orientation during shipping of the syringe that varies from the orientation of the syringe during pre-shipping storage.

31. The population according to claim 30, comprising at least 100 individual syringes.

32. A pharmaceutical product comprising a paliperidone palmitate extended-release injectable suspension within a syringe for administration to a patient suffering from schizophrenia, wherein the syringe has undergone pre-shipping storage and has been shipped, and wherein the syringe has been maintained in an orientation during the shipping that varies from the orientation of the syringe during pre-shipping storage.

33. The pharmaceutical product according to claim 32, wherein the syringe was housed within a container comprising an outer surface that included instructions for maintaining the container during shipping in an orientation that corresponds to the desired orientation of the syringe.

34. The pharmaceutical product according to claim 32 or claim 33, wherein the syringe was housed within a container comprising an outer surface that included markings that indicated an orientation of the container that corresponds to maintaining the desired orientation of the syringe.

35. The pharmaceutical product according to any one of claims 32-34, wherein, following the shipping, the syringe contains no more than about 1.5 mm of residue representing non-resuspended paliperidone palmitate after injection of the suspension.

36. The pharmaceutical product according to any one of claims 32-34, wherein, following the shipping, the syringe contains no more than about 1 mm of residue representing non-resuspended paliperidone palmitate after injection of the suspension.

37. The pharmaceutical product according to any one of claims 32-36, wherein the suspension contains about 273, 410, 546, or 819 mg of paliperidone palmitate.

38. The pharmaceutical product according to any one of claims 32-36, wherein the suspension contains about 1092 or 1560 mg of paliperidone palmitate.

39. The pharmaceutical product according to any one of claims 32-38, wherein the shipping orientation varied from the orientation of the syringe during pre-shipping storage by about 45 degrees to about 135 degrees.

40. The pharmaceutical product according to any one of claims 32-38, wherein the pre-shipping storage orientation was tip down, and the shipping orientation is tip up or substantially horizontal.

41. The pharmaceutical product according to any one of claims 32-38, wherein the pre-shipping storage orientation was tip down, and the shipping orientation is substantially horizontal.

42. The pharmaceutical product of any one of the claims 32-38, wherein the pre-shipping storage orientation of the syringe was tip-down.